Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03949335 · ClinicalTrials.gov registry record · NA

Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens

A NA study of Cataract and Corneal Astigmatism, sponsored by Johnson & Johnson Surgical Vision.

Completed
Registry status
NA
Development phase
272
Enrollment target
15
Study locations

NCT03949335 is a NA study of Cataract and Corneal Astigmatism that has completed, run by Johnson & Johnson Surgical Vision. The registered enrollment target is 272 participants, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (21% higher). The trial reports 15 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03949335, a NA study of Cataract and Corneal Astigmatism, has completed, sponsored by Johnson & Johnson Surgical Vision.

COMPLETED
Registry status
NA
Development phase
272 participants
Enrollment target
15
Study locations

Study Summary

This study will be a prospective, multicenter, bilateral, comparative, three-way masked (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites. Up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted subjects, resulting in approximately 244 evaluable subjects (122 per lens group) at 6 months. After informed consent is obtained and confirmation that all eligibility criteria are met, the eye(s) may be treated according to randomization. After signing the informed consent form, subjects meeting all eligibility criteria will be randomized in a masked fashion to a treatment group: either the investigational IOL Model ZFR00V or the control IOL Model ZCB00. Prior to randomization, the investigator will choose which eye to operate on first for each subject at his/her discretion based on his/her standard clinical practice (e.g., the eye with the worse cataract, poorer best corrected distance vision and/or more severe optical/visual complaints). All subjects are intended to have bilateral cataract surgery with the second eye surgery occurring after the 1-week postoperative exam for the first eye, but no more than 30 days after the first eye surgery. All subjects will be examined through 6 months postoperatively according to the visit schedule

Interventions

  • DEVICE IOL Model ZFR00V
  • DEVICE IOL Model ZCB00

Study Locations (15)

Texas

  • Key-Whitman Eye Center - Dallas
  • Berkeley Eye Institute - Houston
  • Texas Eye and Laser Center - Hurst
  • Lehmann Eye Center - Nacogdoches
  • Focal Point Vision - San Antonio

California

  • Empire Eye & Laser Center - Bakersfield
  • Wolstan & Goldberg Eye Associates - Torrance

Florida

  • Katzen Eye Care & Laser Center - West Palm Beach

Iowa

  • Jones Eye Clinic - Sioux City

Maryland

  • Chesapeake Eye Care & Laser Center - Annapolis

Ohio

  • Cincinnati Eye Institute - Blue Ash

Pennsylvania

  • Scott & Christie and Associates, PC - Cranberry Township

South Carolina

  • Carolina EyeCare Physicians - Mt. Pleasant

Trial Details

FieldValue
Enrollment Target 272 participants
Start Date 2019-07-31
Est. Completion 2020-06-18
Phase NA

Sponsor

Johnson & Johnson Surgical Vision

22 total trials

What the Registry Record Tells You About NCT03949335

The ClinicalTrials.gov registry entry for NCT03949335 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 272 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 225-participant average among 83 other Cataract trials with a reported enrollment target (21% higher). The listed sponsor is Johnson & Johnson Surgical Vision, which has 22 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cataract appearing as the primary indexed condition, and to 2 interventions - of which IOL Model ZFR00V is the first listed.

NCT03949335 reports 15 study locations spanning 10 distinct geographic areas - top geographies include Texas, California, Florida.

Frequently Asked Questions

What is clinical trial NCT03949335 about?

NCT03949335 is a clinical study titled "Clinical Investigation of the Safety and Effectiveness of an Investigational Model of the TECNIS® Intraocular Lens". This study will be a prospective, multicenter, bilateral, comparative, three-way masked (Sponsor, subject and evaluator), randomized clinical investigation conducted at up to 15 sites. Up to 300 subjects will be enrolled to achieve approximately 270 bilaterally implanted subjects, resulting in appro...

What is the current status of trial NCT03949335?

This trial is currently completed. It is a NA study. The enrollment target is 272 participants. The study started on 2019-07-31. Estimated completion is 2020-06-18.

What conditions does trial NCT03949335 study?

This clinical trial studies the following conditions: Cataract, Corneal Astigmatism.

What interventions are being tested in trial NCT03949335?

The interventions under investigation include: IOL Model ZFR00V (DEVICE), IOL Model ZCB00 (DEVICE).

Who is sponsoring clinical trial NCT03949335?

This trial is sponsored by Johnson & Johnson Surgical Vision, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03949335 being conducted?

This trial has 15 study locations across California, Florida, Iowa, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cataract

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.